NCI-2021-00222

NRG-BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (De-Escalation of Breast Radiation - DEBRA Trial).

This research study is investigating whether it's possible to safely reduce the amount of radiation therapy given to women with early-stage, low-risk breast cancer while still effectively treating the disease. This study is for women with Stage I breast cancer which is an early stage where the cancer is small and hasn't spread, Hormone-sensitive breast cancer which means the cancer cells are fueled by hormones like estrogen, HER-2 negative means the cancer doesn't have too much of a protein called HER-2, which is sometimes involved in cancer growth and the oncotype Recurrence Score less than or equal to 18 (low score indicates low risk).

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04852887

Clinical Trial Site: Sinai

To see all available clinical trials click here.